Clinical trials update from the European Society of Cardiology–Heart Failure meeting 2015: AUGMENT‐HF, TITRATION, STOP‐HF, HARMONIZE, LION HEART, MOOD‐HF, and renin–angiotensin inhibitors in patients with heart and renal failure. (20th August 2015)

• Record Type: Journal Article
• Authors: Pellicori, Pierpaolo; Clark, Andrew L.
• Is Part Of: European journal of heart failure. Volume 17:Number 9(2015)
• Page Start: 979
• Page End: 983
• Publication Date: 2015-08-20
• Subjects: Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1002/ejhf.340
• Languages: English
• ISSNs: 1388-9842

Abstract

<abstract abstract-type="main" id="ejhf340-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p id="ejhf340-para-0001">This article provides an overview on the key trials relevant to the pathophysiology, prevention, and treatment of heart failure (HF) presented at the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) annual meeting held in Seville, Spain in May 2015. Trials reported include AUGMENT‐AF (myocardial injections of calcium‐alginate hydrogel), a propensity score‐matched study of renin–angiotensin system antagonists in patients with HF and severe renal dysfunction, HARMONIZE (sodium zirconium cyclosilicate used to bind potassium), TITRATION, comparing two regimes for introducing LCZ696, STOP‐HF, a trial of intramyocardial stromal cell‐derived factor‐1, MOOD‐HF (escitalopram for patients with heart failure and depression), and LION HEART, a trial of intermittent levosimendan therapy. Unpublished reports should be considered as preliminary, since analyses may change in the final publication.</p> </abstract>